Vektor Pharma TF was founded in 2009 by two mechanical engineers and two pharmacists. From the start, the objective was to modernise existing technologies and to implement new ideas in the manufacture and development of transdermal systems. Using intelligent formulation technologies, the company has investigated generic and new substances and developed these into efficient transdermal systems, which are undergoing clinical trials. Until 2017 three developments have successfully passed pilot PK studies. By 2011 the company has overhauled the standard production technology and was in a position to realise developments and manufacturing more efficiently. Since 2012 Vektor Pharma has been offering pharmaceutical analysis and product approval within the scope of a pharmaceutical manufacturing licence. The services of the company are now in demand all over the world. More than 50 % of our turnover is generated outside the European Union – in the USA and Asia, for example.
In 2020 Vektor Pharma has 26 staff members working on formula development, analysis and mechanical engineering. The key research interests of Vektor Pharma to date are the development of novel and well-defined dosage forms (e.g. transdermal systems and therapeutic films) for the controlled drug delivery of active pharmaceutical ingredients. Therefore, Vektor Pharma has the GMP-manufacturing permit for clinical studies (since 2014) and the permits for handling of narcotic drugs under GMPs.
The team of Vektor Pharma consistently pursues the vision of seeing transdermal systems and therapeutic films in every home medicine cabinet by accessing markets for new substances and applications of modern technologies.